Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Feb 18, 2009

Premium

Alan Carter will serve as Agendia's new VP of global business development. Carter formerly served as an executive at BioTrove, Celera, Applied Biosystems, and PerkinElmer.


Pfizer announced the appointment of David Cox as the chief scientific officer of its Target Generation Unit. Cox was a co-founder of Perlegen, and chief scientific officer at the company since its inception in 2000. He was also professor of genetics and pediatrics at the Stanford University School of Medicine as well as the co-director of the Stanford Genome Center.


John Alsobrook has been promoted to vice president and chief operating officer of Exagen Diagnostics. In his new role, Alsobrook will report to Exagen Founder and Interim CEO Waneta Tuttle.

Prior to his new position, Alsobrook was a consultant for Genaissance Pharmaceuticals, Amersham Health, GE Healthcare, and Massachusetts General Hospital. Alsobrook also worked at CuraGen as genetics supervisor for drug discovery and as senior research scientist for pharmacogenomics. From 1996 to 2000, Alsobrook was an associate faculty scientist at Yale School of Medicine Child Study Center, where he investigated inherited psychiatric disorders.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.